Jeremy Wigginton, MD, MBA, FAAFP

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with traditional monitoring based on recent clinical trial data, including research on cardiovascular-risk reduction in noninsulin patients.